SCHEMBL5770967

SCHEMBL5770967

CC(C)(C)OC(=O)N1CCC(/C=C/C=C/C(=O)O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.48
GPR119 Q8TDV5 6/20 0.45
EPHX1 P07099 1/20 0.45
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
THRB P10828 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931015 1.00 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL1722011 0.90 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL1722010 0.90 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL18586916 0.84 HPGD (0.54) HPGDRECQLGPR119EPHX1USP2
SCHEMBL18586918 0.84 HPGD (0.54) HPGDRECQLGPR119EPHX1USP2
SCHEMBL20128945 0.83 HPGD (0.45) HPGDRECQLGPR119EPHX1USP2
SCHEMBL20519800 0.81 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL20519803 0.81 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL22955531 0.81 HPGD (0.50) HPGDRECQLGPR119EPHX1USP2
SCHEMBL25528906 0.80 HPGD (0.53) HPGDRECQLGPR119EPHX1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053214-B2 β-sheet mimetics and composition and methods relating thereto MYRIAD GENETICS, INC. (US) 2006-05-30 US disclosed
US-20060084653-A1 Beta-sheet mimetics and composition and methods relating thereto MYRIAD GENETICS, INCORPORATED (US) 2006-04-20 US disclosed
EP-1482941-A4 BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO MYRIAD GENETICS INC (US) 2006-04-12 EP disclosed
EP-1482941-A1 BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO Myriad Pharmaceuticals, Inc. (US) 2004-12-08 EP disclosed
US-20040014763-A1 beta-sheet mimetics and composition and methods relating thereto MYRIAD PHARMACEUTICALS, INC. (US) 2004-01-22 US disclosed
WO-2003068237-A1 BETA-SHEET MIMETICS AND COMPOSITION AND METHODS RELATING THERETO MYRIAD GENETICS, INC. (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014763-A1 beta-sheet mimetics and composition and methods relating thereto TPSAB1, TPSB2, TPSD1 HPGD 2936/4885RECQL 526/4885GPR119 1083/4885
US-20060084653-A1 Beta-sheet mimetics and composition and methods relating thereto TPSAB1, TPSB2, TPSD1 HPGD 2457/4885RECQL 439/4885GPR119 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.